Skip to main content

Study of Clinical Efficacy of Antimicrobial Therapy Strategy Using Pragmatic Design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF)

General Information

Age Group

Adult

Status

Active

Protocol Number

N/A

Background Information

The purpose of this research study is to compare the impact of an antimicrobial therapy (co-trimoxazole or doxycycline) strategy plus standard care for IPF versus standard care alone on clinical outcomes in patients diagnosed with IPF. Standard care for IPF may include the use of medications including nintedanib and pirfenidone.

Offered At

Inova Heart and Vascular Institute
Advanced Lung Disease and Transplant Clinic
3300 Gallows Road
Falls Church, VA 22042

Principal Investigator

Christopher King, MD

Eligibility Information

  • Written informed consent signed prior to entry into study
  • ≥ 40 years of age
  • Diagnosed with IPF by enrolling investigator

Ineligibility Information

  • Received antimicrobial therapy in the past 30 days for treatment purposes (antibiotic prophylaxis for procedures do not meet criteria, nor do antivirals)
  • Patients who have contraindications to antibiotic therapy such as allergies, renal impairments, or concomitant medications which may cause adverse reactions when combined with antibiotics
  • Pregnant patients or those planning to become pregnant
  • Use of an investigational study agent for IPF therapy within the past 30 days or an IV infusion with a half-life of four weeks
  • Concomitant immunosuppression with azathioprine, mycophenolate, cyclophosphamide, or cyclosporine